IFP Advisors Inc boosted its stake in Sanofi (NYSE:SNY) by 1.9% during the second quarter, Holdings Channel reports. The fund owned 16,621 shares of the company’s stock after buying an additional 304 shares during the period. IFP Advisors Inc’s holdings in Sanofi were worth $796,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Guggenheim Capital LLC boosted its stake in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares in the last quarter. Goodwin Daniel L bought a new stake in shares of Sanofi during the second quarter valued at about $239,000. Cullinan Associates Inc. boosted its stake in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Sanofi during the first quarter valued at about $2,252,000. Finally, Stifel Financial Corp boosted its stake in shares of Sanofi by 8.6% in the first quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares in the last quarter. 9.96% of the stock is owned by hedge funds and other institutional investors.

Shares of Sanofi (NYSE SNY) opened at 47.41 on Friday. The stock has a market capitalization of $119.07 billion, a PE ratio of 11.20 and a beta of 0.88. The company’s 50-day moving average is $48.05 and its 200-day moving average is $46.06. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.

Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The company’s revenue was down 2.3% on a year-over-year basis. Equities research analysts expect that Sanofi will post $3.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sanofi (SNY) Stake Increased by IFP Advisors Inc” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/sanofi-sny-stake-increased-by-ifp-advisors-inc.html.

SNY has been the subject of several research reports. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Argus boosted their price objective on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Friday, June 2nd. Finally, Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.